Breast Cancer

Efficacy of tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer, including patients with brain metastases or visceral disease.

An overview of treatment options for HER2-positive metastatic breast cancer and practical guidance on selecting therapy.

Andrew D. Seidman, MD, presents a case study of a 56-year-old postmenopausal woman diagnosed with stage IIB HR+ breast cancer and leads the discussion on approaching treatment for the given patient.

Dejan Juric, MD, leads the discussion on the role of PIK3CA mutations in HR+ metastatic breast cancer.

Dr Lee Schwartzberg, MD, FASCO, highlights the appropriateness for treating HER2-positive metastatic breast cancer with either neratinib plus capecitabine or margetuximab plus chemotherapy based on evidence revealed by the NALA and SOPHIA clinical trials.

Considerations for initiating trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who received previous treatment with trastuzumab emtansine based on data demonstrated by the DESTINY-Breast01 study.

Halle Moore, MD, discusses the data that support the use of CDK4/6 inhibitors plus endocrine therapy in HR-positive, HER2-negative breast cancer, how to select between available CDK4/6 inhibitors in the metastatic setting, and the current state of this treatment approach for patients with early-stage disease.

The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates, and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic.

Nicholas McAndrew, MD, MSCE, provides final thoughts on findings reported at ASCO 2021 for patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer.

Nicholas McAndrew, MD, MSCE, provides his perspective on real-world clinical outcomes using alpelisib in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer.

Nicholas McAndrew, MD, MSCE, discusses the impact of CDK4/6 therapy duration on alpelisib benefit in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer from the BYLieve trial.

Nicholas McAndrew, MD, MSCE, reviews PIK3CA mutations in HR+/HER2- breast cancer and provides his perspective on the joint analysis of SOLAR-1 and CBYL719X2101 in which patients were given alpelisib and fulvestrant.

Heather L. McArthur, MD, MPH, discusses key advances in breast cancer regarding CDK4/6 inhibitors, PI3K inhibitors, and subcutaneous formulations of standard treatments.

Experts in breast cancer comment on the appropriate patient selection of CDK4/6 inhibitors for the management of HR-positive metastatic breast cancer.

A review of data from key phase 3 clinical trials, including ASCO 2021 updates, assessing the use of CDK4/6 inhibitors with endocrine therapy for the frontline treatment of HR-positive metastatic breast cancer.

Hannah M. Linden, MD, discusses the potential for enobosarm in patients with metastatic breast cancer, data from a phase 2 trial examining its use, and next steps for the agent in the paradigm.

Athenex, Inc. held a Type A meeting with the FDA to discuss the deficiencies raised in the complete response letter issued in March 2021 for the new drug application for oral paclitaxel plus encequidar in the treatment of patients with metastatic breast cancer.

The significance of the HER2CLIMB study of tucatinib in combination with capecitabine and trastuzumab as treatment for patients with HER2-positive metastatic breast cancer.

Current treatment approaches available to treat HER2-positive metastatic breast cancer in the first- and second-line treatment settings.

Thanks to advances in research, targeted therapies, and a more personalized approach to treating patients diagnosed with breast cancer, more surgical options exist for patients with breast cancer patients than ever before.

Nicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Novel therapeutic strategies are poised to expand in adjuvant settings for patients with early-stage disease facing recurrence risks in the treatment paradigms for a range of tumor types after positive data from large phase 3 clinical trials were highlighted at the 2021 American Society of Clinical Oncology Annual Meeting

Considerations for approaching the treatment of HR-positive metastatic breast cancer through insights on key prognostic factors.

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss when it is appropriate to order molecular testing and the impact of testing on the treatment of HR-positive metastatic breast cancer.